Genentech’s Tumor-Agnostic Cancer Drug Approved

Drug Industry Daily
The FDA on Thursday approved Genentech’s Rozlytrek (entrectinib) for adults and adolescents who have cancers with a common biomarker — only the third time the agency has approved a cancer treatment on the basis of a biomarker rather than for treatment of a specific tumor.

To View This Article:


Subscribe To Drug Industry Daily